CRMD — CorMedix Inc.

Summary of CorMedix Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $128.6 million, driven by DEFENCATH ($91.2 million) and Melinta portfolio ($37.4 million).
• Full Year 2025 Revenue: $401.3 million (pro forma), with DEFENCATH contributing $258.8 million.
• Operating Expenses: Q4 operating expenses rose to $48.2 million from $17.1 million year-over-year, reflecting merger-related costs and expanded operations.
• Net Income: $14.0 million for 2025, impacted by a non-cash tax expense of $42.4 million.
• Adjusted EBITDA: $77.2 million for Q4, indicating solid core operating performance.
• Cash Position: Ended Q4 with $148.5 million in cash and equivalents, supported by strong operating cash flow of nearly $100 million.

2. Strategic Updates and Business Highlights

• Acquisition of Melinta Therapeutics: Completed in Q3 2025, contributing to revenue and operational synergies of $35 million.
• DEFENCATH Strategy: Focus on maintaining patient utilization rates post-TDAPA transition and negotiating supply pricing for 2026 and 2027.
• Clinical Development: Progress on RIZEAO and DEFENCATH clinical programs, with Phase III RESPECT data expected in Q2 2026.
• Market Potential: Estimated market opportunities for RIZEAO at $2.5 billion and DEFENCATH in TPN at $500-750 million.

3. Forward Guidance and Outlook

• 2026 DEFENCATH Revenue Guidance: $150 million to $170 million; 2027 guidance of $100 million to $125 million.
• Overall 2026 Revenue Guidance: $300 million to $320 million, with adjusted EBITDA of $100 million to $125 million.
• Focus Areas: Continued discussions with Medicare Advantage providers and potential new customers for DEFENCATH.

4. Bad News, Challenges, or Points of Concern

• Post-TDAPA Transition Risks: The transition from buy-and-bill to bundled reimbursement could lead to price erosion and impact revenue in Q4 2026.
• Legislative Uncertainty: Ongoing discussions regarding TDAPA extension bills are complicated by external factors, including geopolitical events, making timing unpredictable.
• Market Concentration: Heavy reliance on a few large dialysis organizations for DEFENCATH sales, which could pose risks if relationships or contracts change.

5. Notable Q&A Insights

• Customer Conversations: Management expressed optimism about negotiations with dialysis customers to preserve utilization and potentially increase pricing.
• RIZEAO Data Utilization: Emphasis on leveraging positive Phase III data to engage with payers, focusing on reduced drug-drug interactions and improved patient outcomes.
• Inpatient Opportunity for DEFENCATH: Current customer mix is heavily weighted toward a few large players, with potential for growth depending on onboarding new customers.
• Cash Flow Considerations: Operating cash flow is expected to align closely with EBITDA, but inventory management and accrued rebates may impact liquidity in 2026.

This summary reflects a balanced view of CorMedix's performance and strategic direction, highlighting both achievements and potential challenges as the company moves forward.